New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
08:24 EDTKERXKeryx price target raised to $25 from $16 at Maxim
Maxim raised its price target for Keryx shares to $25 on expectations the company is now positioned to launch Zerenex by itself or with a partner following its capital raise. The firm keeps a Buy rating on the stock.
News For KERX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
08:08 EDTKERXKeryx appoints John Neylan, MD, as Chief Medical Officer
Keryx Biopharmaceuticals announced the appointment of John Neylan, MD to the newly created position of Chief Medical Officer. In this role, Dr. Neylan will be responsible for oversight of medical affairs, clinical development and pharmacovigilence at Keryx. Dr. Neylan comes to Keryx from Genzyme, where since 2008 he served in the capacity of SVP, Clinical Development, focusing on specialty metabolic diseases.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use